Rejoyn RWE study in GB
Research type
Research Study
Full title
A real-world, non-interventional study to assess the clinical and economic value of CT-152 for depressive disorder in Great Britain (CT-152 GB Observational Study)
IRAS ID
359851
Contact name
Allan H Young
Contact email
Sponsor organisation
Otsuka Pharmaceutical Europe Ltd.
Duration of Study in the UK
2 years, 2 months, 15 days
Research summary
Depression is a common and serious mental health condition that affects how people feel, think, and function in daily life. Many people do not get the help they need, either because treatments are not effective enough or because access, especially to talking therapies, is limited.
To help address this, new digital tools are being developed. One such tool is Rejoyn, a smartphone app designed to treat depressive symptoms. Rejoyn has received a UK Conformity Assessment (UKCA) mark and certification under the NHS Digital Technology Assessment Criteria (DTAC). It offers a self-guided program that includes short therapeutic lessons based based on cognitive behavioural therapy(CBT) and brain exercises help improve emotional processing and symptoms of depression. The app also sends daily text messages to reinforce key skills and encourage engagement. The treatment lasts for 6 weeks, with an optional 4-week extension where therapeutic lessons remains accessible but no new therapy is introduced.
A recent clinical trial in the US showed that Rejoyn can reduce symptoms of depression. However, more evidence is needed on how well it works in real-world settings in Great Britain.
This study aims to understand how effective Rejoyn is when used alongside usual care for depression. It will also explore how long any benefits last, how the app affects use of healthcare services, and how well people stick with the programme. The findings will help determine whether Rejoyn could be a useful addition to current treatment options.
The study will include around 300 adult participants using Rejoyn and another 300 receiving usual care without the app.
REC name
West Midlands - Solihull Research Ethics Committee
REC reference
25/WM/0203
Date of REC Opinion
14 Oct 2025
REC opinion
Favourable Opinion